GlassScriptPhysician profile
Rebecca D Hardesty
NPI 1578831251
$3,397.08
in general payments reported to CMS, 2019-2025
36 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $756 · 2023: $868 · 2024: $587 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.09 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $391.49 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $239.33 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $203.56 | 2024-2025 | Veozah |
| Myovant Sciences INC. | $195.15 | 2021-2022 | |
| Exeltis, USA INC. | $184.46 | 2021-2025 | Slynd |
| Organon LLC | $169.25 | 2021-2025 | Nexplanon |
| Shield Therapeutics INC | $145.09 | 2022-2025 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $98.22 | 2021-2025 | |
| Millicent US INC | $87.36 | 2022-2025 | Intrarosa, Femring |
| Pfizer INC. | $79.16 | 2024 | |
| Smith+Nephew, INC. | $67.05 | 2024-2025 | Stravix, Pico 14 |
| Therapeuticsmd, INC. | $55.23 | 2021-2022 | |
| Avion Pharmaceuticals | $49.08 | 2021-2023 | Balcoltra |
| Axonics, INC. | $48.58 | 2022-2023 | Axonics |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $37.19 | 2025 | |
| Amgen INC. | $37.15 | 2021-2022 | |
| Agile Therapeutics, INC. | $36.26 | 2021-2024 | Twirla |
| Lupin INC. | $35.35 | 2021 | |
| Minerva Surgical, INC | $33.39 | 2021 | |
| Mylan Pharmaceuticals INC. | $32.17 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.62 | 2023 | Quviviq |
| Sage Therapeutics, LLC | $30.41 | 2025 | Zurzuvae |
| Acessa Health INC. | $30.14 | 2021 | |
| Medtronic, INC. | $24.35 | 2022 | |
| Innovation Technologies INC | $24.21 | 2023 | Irrisept |
| Integra Lifesciences Corporation | $22.01 | 2024 | Medihoney, Biofix, Biodoptix |
| Provepharm INC. | $21.00 | 2025 | Bludigo |
| Pacira Pharmaceuticals Incorporated | $20.87 | 2024 | Exparel |
| Channel Medsystems, INC. | $19.14 | 2023 | |
| Mycovia Pharmaceuticals, INC. | $19.08 | 2023 | Vivjoa |
| Convatec INC. | $17.18 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.81 | 2025 | Qelbree |
| Exact Sciences Corporation | $15.19 | 2025 | Cologuard Collection Kit |
| Ethicon US, LLC | $13.49 | 2024 | Surgicel Nu-Knit, Stratafix, Enseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Hardesty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.